Emerging from the leishmaniasis L205 lead optimization series after showing great efficacy in vivo in both mouse and hamster models for visceral leishmaniasis, DNDI-6174 was nominated as a pre-clinical candidate for visceral leishmaniasis in 2019.

Project updates

2019

Planning is underway to start pre-clinical activities in 2020.